150 related articles for article (PubMed ID: 32681919)
1. Insights from Pharmacovigilance: Gastrointestinal-Related Immune Checkpoint Inhibitor Adverse Events.
Reese SW; Marchese M; McNabb-Baltar J
Gastroenterology; 2020 Oct; 159(4):1195-1200.e1. PubMed ID: 32681919
[No Abstract] [Full Text] [Related]
2. Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database.
Anquetil C; Salem JE; Lebrun-Vignes B; Touhami S; Desbois AC; Maalouf G; Domont F; Allenbach Y; Cacoub P; Bodaghi B; Saadoun D
J Autoimmun; 2020 Jul; 111():102454. PubMed ID: 32303423
[TBL] [Abstract][Full Text] [Related]
3. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution.
Anquetil C; Salem JE; Lebrun-Vignes B; Johnson DB; Mammen AL; Stenzel W; Léonard-Louis S; Benveniste O; Moslehi JJ; Allenbach Y
Circulation; 2018 Aug; 138(7):743-745. PubMed ID: 30359135
[No Abstract] [Full Text] [Related]
5. Pulmonary hypertension reported with immune checkpoint inhibitors: a pharmacovigilance study.
Palassin P; Maria ATJ; Ladhari C; Quantin X; Montani D; Bourdin A; Boissin C; Fesler P; Hillaire-Buys D; Guilpain P; Faillie JL
Cancer Immunol Immunother; 2022 Dec; 71(12):3093-3097. PubMed ID: 35616698
[TBL] [Abstract][Full Text] [Related]
6. Population-Based Frequency of Ophthalmic Adverse Events in Melanoma, Other Cancers, and After Immune Checkpoint Inhibitor Treatment.
Braun D; Getahun D; Chiu VY; Coleman AL; Holland GN; Yu F; Gordon LK; Sun MM
Am J Ophthalmol; 2021 Apr; 224():282-291. PubMed ID: 33359682
[TBL] [Abstract][Full Text] [Related]
7. Lessons from Pharmacovigilance: Pulmonary Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.
Reese SW; Cone E; Marchese M; Garcia B; Chou W; Ayub A; Kilbridge K; Weinhouse G; Trinh QD
Lung; 2021 Apr; 199(2):199-211. PubMed ID: 33616727
[TBL] [Abstract][Full Text] [Related]
8. Thyroiditis and immune check point inhibitors: the post-marketing experience using the French National Pharmacovigilance database.
Garon-Czmil J; Petitpain N; Rouby F; Sassier M; Babai S; Yelehe-Okouma M; Weryha G; Klein M; Gillet P
Fundam Clin Pharmacol; 2019 Apr; 33(2):241-249. PubMed ID: 30308083
[TBL] [Abstract][Full Text] [Related]
9. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database.
Sato K; Mano T; Iwata A; Toda T
J Neurooncol; 2019 Oct; 145(1):1-9. PubMed ID: 31452071
[TBL] [Abstract][Full Text] [Related]
10. Increased risk of immune checkpoint inhibitor-induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?
Kähler KC; Kosova K; Bohne AS; Schreiber S; Hauschild A
Eur J Cancer; 2020 Oct; 138():169-171. PubMed ID: 32890812
[No Abstract] [Full Text] [Related]
11. Hematological toxicities in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019.
Ye X; Hu F; Zhai Y; Qin Y; Xu J; Guo X; Zhuang Y; He J
Hematol Oncol; 2020 Oct; 38(4):565-575. PubMed ID: 32383782
[TBL] [Abstract][Full Text] [Related]
12. Comment on: "Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis".
Noguchi Y; Yan M
Int J Cancer; 2023 Jul; 153(1):238-239. PubMed ID: 36891933
[No Abstract] [Full Text] [Related]
13. Reply to: Comments on "Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis".
Gu T; Lin A; Wang H; Zhang J; Luo P
Int J Cancer; 2023 Jul; 153(1):240-242. PubMed ID: 36891965
[No Abstract] [Full Text] [Related]
14. Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity.
Escudier M; Cautela J; Malissen N; Ancedy Y; Orabona M; Pinto J; Monestier S; Grob JJ; Scemama U; Jacquier A; Lalevee N; Barraud J; Peyrol M; Laine M; Bonello L; Paganelli F; Cohen A; Barlesi F; Ederhy S; Thuny F
Circulation; 2017 Nov; 136(21):2085-2087. PubMed ID: 29158217
[No Abstract] [Full Text] [Related]
15. Gastrointestinal toxicities associated with immune checkpoint inhibitors: a disproportionality analysis leveraging VigiBase, the WHO Adverse Drug Reaction Database.
Huang S; Bai X; Fang T; Guo Y; Zheng K; Lin X
J Zhejiang Univ Sci B; 2021 Feb; 22(2):156-164. PubMed ID: 33615756
[TBL] [Abstract][Full Text] [Related]
16. Underreporting of Major Cardiac Adverse Events With Immune Checkpoint Inhibitors in Clinical Trials: Importance of Postmarketing Pharmacovigilance Surveys.
Palassin P; Faillie JL; Coustal C; Quantin X; Topart D; Roubille F; Maria ATJ
J Clin Oncol; 2023 Feb; 41(5):1154-1156. PubMed ID: 36318740
[No Abstract] [Full Text] [Related]
17. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
18. Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma.
Zhao JJ; Wen XZ; Ding Y; Li DD; Zhu BY; Li JJ; Weng DS; Zhang X; Zhang XS
Aging (Albany NY); 2020 Jun; 12(11):10663-10675. PubMed ID: 32516130
[TBL] [Abstract][Full Text] [Related]
19. Immune-related cutaneous adverse events: A new opportunity for allergists and clinical immunologists.
Leung DYM
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):607. PubMed ID: 34049668
[No Abstract] [Full Text] [Related]
20. Immune checkpoint inhibitor associated neurotoxicity: Much more than meets the eye.
Raibagkar P
Immunol Lett; 2020 May; 221():72-74. PubMed ID: 32092358
[No Abstract] [Full Text] [Related]
[Next] [New Search]
